Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. AML (including secondary AML) diagnosed as per WHO criteria~2. For relapsed/refractory subjects only:~   * Subjects age ≥ 18 years with relapsed or refractory AML after ≤ 2 prior induction regimens, at least one containing anthracyclines~  * Medically eligible to receive MEC~  * Absolute blast count (ABC) ≤ 40,000/mm~3. For treatment-naïve subjects only:~   * Subjects ≥ 60 years of age with newly diagnosed AML~  * Medically eligible to receive 7+3 cytarabine/idarubicin~  * ABC count ≤ 40,000/mm~4. ECOG performance status 0-2~5. Hemodynamically stable and adequate organ function~Exclusion criteria:~1. Acute promyelocytic leukemia~2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)~3. Active signs or symptoms of CNS involvement by malignancy~4. No prior G-CSF, GM-CSF or plerixafor within 14 days of study drug dosing~5. Known history or evidence of active hepatitis A, B, or C or HIV~6. Uncontrolled acute life threatening bacterial, viral or fungal infection~7. Active graft versus host disease (GVHD) ≥ Grade 2 or extensive chronic GVHD requiring immunosuppressive therapy~8. Hematopoietic stem cell transplantation ≤ 4 months of dosing~9. Clinically significant cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Phase I) (Type: EXPERIMENTAL): GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
- Arm B (Phase II Arm A) (Type: EXPERIMENTAL): GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
- Arm C (Phase II Arm B) (Type: EXPERIMENTAL): GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older

Based on this trial design, predict the completion outcome and termination type (if applicable).